Mingfei Dong, Donatello Telesca, Catherine Sugar, Frederick Shic, Adam Naples, Scott P Johnson, Beibin Li, Adham Atyabi, Minhang Xie, Sara J Webb, Shafali Jeste, Susan Faja, April R Levin, Geraldine Dawson, James C McPartland, Damla Şentürk
{"title":"用于研究眼动跟踪实验中跨试验时间的共同趋势的功能模型。","authors":"Mingfei Dong, Donatello Telesca, Catherine Sugar, Frederick Shic, Adam Naples, Scott P Johnson, Beibin Li, Adham Atyabi, Minhang Xie, Sara J Webb, Shafali Jeste, Susan Faja, April R Levin, Geraldine Dawson, James C McPartland, Damla Şentürk","doi":"10.1007/s12561-022-09354-6","DOIUrl":null,"url":null,"abstract":"<p><p>Eye tracking (ET) experiments commonly record the continuous trajectory of a subject's gaze on a two-dimensional screen throughout repeated presentations of stimuli (referred to as trials). Even though the continuous path of gaze is recorded during each trial, commonly derived outcomes for analysis collapse the data into simple summaries, such as looking times in regions of interest, latency to looking at stimuli, number of stimuli viewed, number of fixations or fixation length. In order to retain information in trial time, we utilize functional data analysis (FDA) for the first time in literature in the analysis of ET data. More specifically, novel functional outcomes for ET data, referred to as viewing profiles, are introduced that capture the common gazing trends across trial time which are lost in traditional data summaries. Mean and variation of the proposed functional outcomes across subjects are then modeled using functional principal components analysis. Applications to data from a visual exploration paradigm conducted by the Autism Biomarkers Consortium for Clinical Trials showcase the novel insights gained from the proposed FDA approach, including significant group differences between children diagnosed with autism and their typically developing peers in their consistency of looking at faces early on in trial time.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112660/pdf/nihms-1842687.pdf","citationCount":"0","resultStr":"{\"title\":\"A functional model for studying common trends across trial time in eye tracking experiments.\",\"authors\":\"Mingfei Dong, Donatello Telesca, Catherine Sugar, Frederick Shic, Adam Naples, Scott P Johnson, Beibin Li, Adham Atyabi, Minhang Xie, Sara J Webb, Shafali Jeste, Susan Faja, April R Levin, Geraldine Dawson, James C McPartland, Damla Şentürk\",\"doi\":\"10.1007/s12561-022-09354-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Eye tracking (ET) experiments commonly record the continuous trajectory of a subject's gaze on a two-dimensional screen throughout repeated presentations of stimuli (referred to as trials). Even though the continuous path of gaze is recorded during each trial, commonly derived outcomes for analysis collapse the data into simple summaries, such as looking times in regions of interest, latency to looking at stimuli, number of stimuli viewed, number of fixations or fixation length. In order to retain information in trial time, we utilize functional data analysis (FDA) for the first time in literature in the analysis of ET data. More specifically, novel functional outcomes for ET data, referred to as viewing profiles, are introduced that capture the common gazing trends across trial time which are lost in traditional data summaries. Mean and variation of the proposed functional outcomes across subjects are then modeled using functional principal components analysis. Applications to data from a visual exploration paradigm conducted by the Autism Biomarkers Consortium for Clinical Trials showcase the novel insights gained from the proposed FDA approach, including significant group differences between children diagnosed with autism and their typically developing peers in their consistency of looking at faces early on in trial time.</p>\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112660/pdf/nihms-1842687.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12561-022-09354-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/9/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12561-022-09354-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
眼动追踪(ET)实验通常记录受试者在二维屏幕上重复呈现刺激物(称为试验)时的连续注视轨迹。尽管在每次试验中都记录了连续的注视轨迹,但通常得出的分析结果会将数据折叠成简单的摘要,如在感兴趣区域的注视时间、注视刺激物的潜伏期、注视刺激物的数量、固定次数或固定长度。为了保留试验时间的信息,我们首次在文献中利用功能数据分析(FDA)来分析 ET 数据。更具体地说,我们为 ET 数据引入了新的功能结果,即 "注视轮廓",它能捕捉整个试验时间内的共同注视趋势,而这些趋势在传统的数据总结中会丢失。然后使用功能主成分分析法对所提出的功能结果在不同受试者之间的平均值和变化进行建模。自闭症生物标记物临床试验联盟(Autism Biomarkers Consortium for Clinical Trials)进行的视觉探索范式的数据应用,展示了从拟议的 FDA 方法中获得的新见解,包括被诊断患有自闭症的儿童与发育正常的同龄人在试验时间早期注视人脸的一致性方面存在的显著群体差异。
A functional model for studying common trends across trial time in eye tracking experiments.
Eye tracking (ET) experiments commonly record the continuous trajectory of a subject's gaze on a two-dimensional screen throughout repeated presentations of stimuli (referred to as trials). Even though the continuous path of gaze is recorded during each trial, commonly derived outcomes for analysis collapse the data into simple summaries, such as looking times in regions of interest, latency to looking at stimuli, number of stimuli viewed, number of fixations or fixation length. In order to retain information in trial time, we utilize functional data analysis (FDA) for the first time in literature in the analysis of ET data. More specifically, novel functional outcomes for ET data, referred to as viewing profiles, are introduced that capture the common gazing trends across trial time which are lost in traditional data summaries. Mean and variation of the proposed functional outcomes across subjects are then modeled using functional principal components analysis. Applications to data from a visual exploration paradigm conducted by the Autism Biomarkers Consortium for Clinical Trials showcase the novel insights gained from the proposed FDA approach, including significant group differences between children diagnosed with autism and their typically developing peers in their consistency of looking at faces early on in trial time.